1
NRNP 6540 FINAL EXAM FULL PACKAGE
QUESTIONS ANSWERS AND RATIONALES 2026-27
LATEST UPDATED VERSION
INSTANT DOWNLOAD PDF..!!
INTRODUCTION
The NRNP 6540 Advanced Practice Care of Older Adults Final Examination is a
comprehensive, high-stakes evaluation designed for advanced practice nursing students,
particularly those tracking toward adult-gerontology primary care nurse practitioner
certification. This examination assesses a clinician's synthesis of complex physiological,
psychological, and sociological aspects of aging. Competency in this arena is crucial because
older adults exhibit atypical disease presentations, complex multi-system comorbidities, and
altered pharmacokinetic and pharmacodynamic responses. The exam evaluates diagnostic
reasoning, evidence-based chronic disease management, functional assessment, and ethical
decision-making in elder care.
This meticulously curated question bank contains advanced, application-level, scenario-
based multiple-choice questions modeled directly after the official curriculum blueprint. By
targeting high-order cognitive processes, this package ensures you master subtle clinical
nuances, differentiate confusingly similar distractors, and confidently pass the examination
on your first attempt.
CORE DOMAINS TESTED
• Domain 1: Health Promotion, Protection, and Disease Prevention – Focuses on
screening intervals, immunisation schedules (including pneumococcal and shingles
updates), risk reduction strategies, and functional maintenance in the elderly.
• Domain 2: Assessment of Acute and Chronic Illnesses – Covers atypical
presentations of acute processes (e.g., silent MI, painless peritonitis, afebrile
bacteremia) and comprehensive geriatric syndromes such as frailty, falls, and
pressure ulcers.
• Domain 3: Advanced Pharmacology and Safety (Geriatric Pharmacotherapy) –
Evaluates the clinical application of the AGS Beers Criteria, identification of
prescribing cascades, adjustments for altered renal/hepatic clearance, and
management of polypharmacy.
• Domain 4: Differential Diagnosis and Management of Neurocognitive and
Psychiatric Disorders – Emphasises the clinical differentiation and management of
the "3 Ds": Delirium, Dementia, and Depression, as well as late-life psychoses.
,2
• Domain 5: Socio-Cultural, Ethical, and Legal Dimensions of Care – Focuses on
palliative care, advanced directives, surrogate decision-making, elder abuse
identification, and transition-of-care optimization.
Q1: An 84-year-old female resident of a skilled nursing facility
presents with an abrupt onset of visual hallucinations, mild agitation,
and a fluctuating level of consciousness over the last 36 hours. Her
past medical history includes stable moderate Alzheimer's disease.
On examination, her vitals are: T 37.9°C, HR 102 bpm, BP 104/62
mmHg, RR 20 bpm. A review of her chart reveals she was started on
amitriptyline for diabetic neuropathy 5 days ago. What is the most
appropriate initial diagnostic and management strategy?
A) Increase her scheduled atypical antipsychotic dose to manage
worsening behavioral symptoms of dementia.
B) Discontinue amitriptyline, obtain a urinalysis with reflex culture,
and initiate a comprehensive delirium evaluation.
C) Order an urgent non-contrast CT scan of the head to rule out an
acute ischemic stroke.
D) Administer a loading dose of donepezil to reverse the acute
neurocognitive decline.
Rationale: The correct answer is B because the patient exhibits an
acute, fluctuating change in mental status and attention, hallmarks of
delirium, superimposed on her baseline dementia. Amitriptyline is a
highly anticholinergic tricyclic antidepressant listed explicitly on the
AGS Beers Criteria as potentially inappropriate for older adults due to
the extreme risk of precipitating central nervous system toxicity and
delirium. Furthermore, her low-grade fever and tachycardia require
screening for systemic infectious precipitants like a urinary tract
infection. Option A is incorrect because using antipsychotics to
manage a drug-induced or metabolic delirium without addressing the
root cause is inappropriate and increases mortality risks in dementia.
,3
Option C is incorrect because, while structural lesions must be
considered, the immediate presentation aligns with toxic-
metabolic/infectious delirium rather than focal stroke signs. Option D
is incorrect because donepezil is a long-term maintenance therapy for
Alzheimer's and will not reverse an acute delirium caused by
anticholinergic toxicity.
Q2: A 79-year-old male with a history of Stage 3b Chronic Kidney
Disease (eGFR 38 mL/min/1.73m²) and osteoarthritis presents with
severe, acute pain and swelling in his right first metatarsophalangeal
joint. A joint aspirate confirms the presence of negatively birefringent
needle-shaped crystals. Which of the following pharmacological
agents is the safest first-line selection for managing this acute flare?
A) Indomethacin 50 mg orally three times daily.
B) Prednisone 30 mg orally daily tapered over 5 to 10 days.
C) Colchicine 1.2 mg followed by 0.6 mg one hour later, then 0.6 mg
twice daily indefinitely.
D) Allopurinol 300 mg orally daily initiated immediately.
Rationale: The correct answer is B. Systemic or intra-articular
corticosteroids are the preferred and safest first-line treatment for
acute gout flares in patients with significant renal impairment (Stage
3 or worse CKD). Option A is incorrect because indomethacin and
other non-selective systemic NSAIDs are contraindicated in advanced
CKD due to the risk of precipitating acute kidney injury, worsening
hypertension, and causing fluid retention. Option C is incorrect
because, while colchicine can be used for acute flares, the dose must
be strictly adjusted for renal impairment, and using it at high
maintenance doses indefinitely is toxic. Option D is incorrect because
allopurinol is a urate-lowering therapy that should not be initiated
during an acute flare, as abrupt shifts in serum uric acid levels can
prolong or worsen the acute joint inflammation.
, 4
Q3: A 72-year-old male comes to the clinic for a routine wellness
visit. He has a history of controlled hypertension but is otherwise
healthy and independent. He reports he received one dose of
PPSV23 at age 62 following a splenectomy, and a dose of PCV13 at
age 65. According to the current CDC/ACIP pneumococcal
immunisation guidelines for older adults, what is the most
appropriate recommendation for him?
A) Administer one dose of PCV20 today to complete his lifetime
pneumococcal coverage.
B) Administer a second dose of PPSV23 today, as 10 years have
passed since his first dose.
C) Administer one dose of PPSV23 today to complete his age-65-
and-older recommendation.
D) No further pneumococcal immunisations are indicated because he
has already received both conjugate and polysaccharide vaccines.
Rationale: The correct answer is C. Under current ACIP guidelines,
adults who previously received PCV13 at or after age 65 should
complete their pneumococcal vaccine series by receiving a dose of
PPSV23. Since his first PPSV23 dose was given prior to age 65 (at age
62), he requires an additional dose of PPSV23 at or after age 65 to
ensure long-term protection, provided at least 5 years have elapsed
since the pre-65 polysaccharide dose. Option A is incorrect because
PCV20 is generally not recommended if a patient has already
received PCV13, unless specific shared clinical decision-making or
unique risk profiles apply. Option B is incorrect because, while he does
need PPSV23, the rationale is satisfying the post-65 routine
requirement, not a generic 10-year booster rule. Option D is incorrect
because omitting the post-65 PPSV23 dose leaves the patient under-
immunised based on his early-life splenectomy chronology.
NRNP 6540 FINAL EXAM FULL PACKAGE
QUESTIONS ANSWERS AND RATIONALES 2026-27
LATEST UPDATED VERSION
INSTANT DOWNLOAD PDF..!!
INTRODUCTION
The NRNP 6540 Advanced Practice Care of Older Adults Final Examination is a
comprehensive, high-stakes evaluation designed for advanced practice nursing students,
particularly those tracking toward adult-gerontology primary care nurse practitioner
certification. This examination assesses a clinician's synthesis of complex physiological,
psychological, and sociological aspects of aging. Competency in this arena is crucial because
older adults exhibit atypical disease presentations, complex multi-system comorbidities, and
altered pharmacokinetic and pharmacodynamic responses. The exam evaluates diagnostic
reasoning, evidence-based chronic disease management, functional assessment, and ethical
decision-making in elder care.
This meticulously curated question bank contains advanced, application-level, scenario-
based multiple-choice questions modeled directly after the official curriculum blueprint. By
targeting high-order cognitive processes, this package ensures you master subtle clinical
nuances, differentiate confusingly similar distractors, and confidently pass the examination
on your first attempt.
CORE DOMAINS TESTED
• Domain 1: Health Promotion, Protection, and Disease Prevention – Focuses on
screening intervals, immunisation schedules (including pneumococcal and shingles
updates), risk reduction strategies, and functional maintenance in the elderly.
• Domain 2: Assessment of Acute and Chronic Illnesses – Covers atypical
presentations of acute processes (e.g., silent MI, painless peritonitis, afebrile
bacteremia) and comprehensive geriatric syndromes such as frailty, falls, and
pressure ulcers.
• Domain 3: Advanced Pharmacology and Safety (Geriatric Pharmacotherapy) –
Evaluates the clinical application of the AGS Beers Criteria, identification of
prescribing cascades, adjustments for altered renal/hepatic clearance, and
management of polypharmacy.
• Domain 4: Differential Diagnosis and Management of Neurocognitive and
Psychiatric Disorders – Emphasises the clinical differentiation and management of
the "3 Ds": Delirium, Dementia, and Depression, as well as late-life psychoses.
,2
• Domain 5: Socio-Cultural, Ethical, and Legal Dimensions of Care – Focuses on
palliative care, advanced directives, surrogate decision-making, elder abuse
identification, and transition-of-care optimization.
Q1: An 84-year-old female resident of a skilled nursing facility
presents with an abrupt onset of visual hallucinations, mild agitation,
and a fluctuating level of consciousness over the last 36 hours. Her
past medical history includes stable moderate Alzheimer's disease.
On examination, her vitals are: T 37.9°C, HR 102 bpm, BP 104/62
mmHg, RR 20 bpm. A review of her chart reveals she was started on
amitriptyline for diabetic neuropathy 5 days ago. What is the most
appropriate initial diagnostic and management strategy?
A) Increase her scheduled atypical antipsychotic dose to manage
worsening behavioral symptoms of dementia.
B) Discontinue amitriptyline, obtain a urinalysis with reflex culture,
and initiate a comprehensive delirium evaluation.
C) Order an urgent non-contrast CT scan of the head to rule out an
acute ischemic stroke.
D) Administer a loading dose of donepezil to reverse the acute
neurocognitive decline.
Rationale: The correct answer is B because the patient exhibits an
acute, fluctuating change in mental status and attention, hallmarks of
delirium, superimposed on her baseline dementia. Amitriptyline is a
highly anticholinergic tricyclic antidepressant listed explicitly on the
AGS Beers Criteria as potentially inappropriate for older adults due to
the extreme risk of precipitating central nervous system toxicity and
delirium. Furthermore, her low-grade fever and tachycardia require
screening for systemic infectious precipitants like a urinary tract
infection. Option A is incorrect because using antipsychotics to
manage a drug-induced or metabolic delirium without addressing the
root cause is inappropriate and increases mortality risks in dementia.
,3
Option C is incorrect because, while structural lesions must be
considered, the immediate presentation aligns with toxic-
metabolic/infectious delirium rather than focal stroke signs. Option D
is incorrect because donepezil is a long-term maintenance therapy for
Alzheimer's and will not reverse an acute delirium caused by
anticholinergic toxicity.
Q2: A 79-year-old male with a history of Stage 3b Chronic Kidney
Disease (eGFR 38 mL/min/1.73m²) and osteoarthritis presents with
severe, acute pain and swelling in his right first metatarsophalangeal
joint. A joint aspirate confirms the presence of negatively birefringent
needle-shaped crystals. Which of the following pharmacological
agents is the safest first-line selection for managing this acute flare?
A) Indomethacin 50 mg orally three times daily.
B) Prednisone 30 mg orally daily tapered over 5 to 10 days.
C) Colchicine 1.2 mg followed by 0.6 mg one hour later, then 0.6 mg
twice daily indefinitely.
D) Allopurinol 300 mg orally daily initiated immediately.
Rationale: The correct answer is B. Systemic or intra-articular
corticosteroids are the preferred and safest first-line treatment for
acute gout flares in patients with significant renal impairment (Stage
3 or worse CKD). Option A is incorrect because indomethacin and
other non-selective systemic NSAIDs are contraindicated in advanced
CKD due to the risk of precipitating acute kidney injury, worsening
hypertension, and causing fluid retention. Option C is incorrect
because, while colchicine can be used for acute flares, the dose must
be strictly adjusted for renal impairment, and using it at high
maintenance doses indefinitely is toxic. Option D is incorrect because
allopurinol is a urate-lowering therapy that should not be initiated
during an acute flare, as abrupt shifts in serum uric acid levels can
prolong or worsen the acute joint inflammation.
, 4
Q3: A 72-year-old male comes to the clinic for a routine wellness
visit. He has a history of controlled hypertension but is otherwise
healthy and independent. He reports he received one dose of
PPSV23 at age 62 following a splenectomy, and a dose of PCV13 at
age 65. According to the current CDC/ACIP pneumococcal
immunisation guidelines for older adults, what is the most
appropriate recommendation for him?
A) Administer one dose of PCV20 today to complete his lifetime
pneumococcal coverage.
B) Administer a second dose of PPSV23 today, as 10 years have
passed since his first dose.
C) Administer one dose of PPSV23 today to complete his age-65-
and-older recommendation.
D) No further pneumococcal immunisations are indicated because he
has already received both conjugate and polysaccharide vaccines.
Rationale: The correct answer is C. Under current ACIP guidelines,
adults who previously received PCV13 at or after age 65 should
complete their pneumococcal vaccine series by receiving a dose of
PPSV23. Since his first PPSV23 dose was given prior to age 65 (at age
62), he requires an additional dose of PPSV23 at or after age 65 to
ensure long-term protection, provided at least 5 years have elapsed
since the pre-65 polysaccharide dose. Option A is incorrect because
PCV20 is generally not recommended if a patient has already
received PCV13, unless specific shared clinical decision-making or
unique risk profiles apply. Option B is incorrect because, while he does
need PPSV23, the rationale is satisfying the post-65 routine
requirement, not a generic 10-year booster rule. Option D is incorrect
because omitting the post-65 PPSV23 dose leaves the patient under-
immunised based on his early-life splenectomy chronology.
